ArticleJournal of thoracic disease2022

Neoadjuvant gefitinib therapy: a potential standard therapy for non-small cell lung cancer.

Tomoki Nishida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.